FDA Approves Emergent's ACAM2000 Mpox Vaccine, Stock Soars 23%

Aug 30, 2024, 05:50 AM

The U.S. Food and Drug Administration (FDA) has approved the expanded use of Emergent BioSolutions' ACAM2000®, a live smallpox vaccine, to include individuals at high risk for mpox infection. This approval comes amid ongoing mpox outbreaks across Africa and other regions, highlighting a critical public health challenge. Following the FDA's decision, Emergent BioSolutions' stock saw a significant increase, soaring by 23%. The ACAM2000 vaccine, initially developed for smallpox, will now play a crucial role in addressing the public health challenge posed by mpox.